Universal Ibogaine Inc.IBO.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · universalibogaine.com

Universal Ibogaine Inc. is a Canadian life sciences company that develops and operates addiction treatment clinics and conducts clinical research into ibogaine-based therapies. The company is focused on addressing the opioid crisis and is pioneering regulatory approval for ibogaine treatment in Canada, with studies targeting addiction to opioids, alcohol, and cocaine. Headquartered in Calgary, Alberta.

Key ratios

FCF / Sales

-32.2%TTM

2024 -39.3%2023 -141.5%2022 -413.6%

Net margin

-71.7%TTM

2024 -88.0%2023 -232.1%

ROA

-9.5%TTM

2024 -11.3%2023 -21.7%2022 -57.6%

ROE

-149.6%2024

2023 -84.0%2022 -304.8%

Revenue growth

-11.7%TTM

2024 126.3%2023 -3.8%

Recent news

Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process 2026-01-02 · TheNewsWire

Track IBO.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer